Darolutamide is a new drug developed to treat prostate cancer that has come back after failure of hormone injections .

Dr Fizazi from France presented the study at the American Society of Clinical Oncology meeting at Chicago.

The drug was found to be highly effective at controlling the cancer and had a significant impact on the ability of prostate cancer to spread.

Reference

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only. See your own doctor to discuss concerns and options relevant for you.